Table 3 Currently Eligible Patient Population for the COPPAR registrya
From: Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)
| Â | Psoriasis (NÂ =Â 1694)** | Psoriatic Arthritis (NÂ =Â 1028)** | Total Cohort (NÂ =Â 2484) |
|---|---|---|---|
N (%) or mean (+/−SD) | |||
Demographics/Health Services Use | |||
 Age, mean, years | 55.5 (± 16.2) | 55.9 (± 14.2) | 55.5 (± 15.6) |
 Male sex | 788 (46.5) | 494 (48.1) | 1162 (46.8) |
 Race | |||
  White | 1382 (81.6) | 917 (89.2) | 2099 (84.5) |
  Black | 61 (3.6) | 19 (1.8) | 69 (2.8) |
  Hispanic | 127 (7.5) | 23 (2.2) | 139 (5.6) |
  Other | 124 (7.3) | 69 (6.7) | 177 (7.1) |
 Patients with visits in 2014 for PsO/PsA | 1404 (82.9) | 841 (81.8) | 2068 (83.3) |
 Visits in 2014 for PsO/PsA, mean | 3 (± 5) | 3 (± 2) | 3 (± 4) |
Comorbidities | |||
 Diabetes | 318 (18.8) | 169 (16.4) | 420 (16.9) |
 Hyperlipidemia | 740 (43.7) | 302 (29.4) | 942 (37.9) |
 Hypertension | 835 (49.3) | 422 (41.1) | 1110 (44.7) |
 Body mass index, mean | 29.5 (± 7.7) | 29.8 (± 6.9) | 29.6 (± 7.4) |
Psoriasis and Psoriatic Arthritis Characteristics | |||
 Prednisone use | 470 (27.7) | 478 (46.5) | 833 (33.5) |
 Current NSAID use | 107 (6.3) | 153 (14.9) | 248 (10.0) |
 Current/prior MTX use | 335 (19.8) | 616 (59.9) | 801 (32.2) |
 Current/prior TNFi | 350 (20.7) | 675 (65.7) | 858 (34.5) |
 Current/prior topical PsO | 1625 (95.9) | 728 (70.8) | 2123 (85.5) |